Clinical Trial

Mindfulness Texting for Medication Adherence and Chronic Pain Management

Study acronym: MiMA
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to examine the effects of reminder and mindfulness text messages based on integrated Acceptance and Commitment Therapy and Mindfulness Based Relapse Prevention (ACT+MBRP) on medication adherence and managing craving, pain, mindfulness, and withdrawal symptoms in people taking medications for opioid use disorder and with chronic pain through assessment questions collected six times daily during the course of treatment. The main questions it aims to answer are: 1. Do daily medication reminder text messages increase medication adherence for people taking medications for opioid use disorder? 2. To what extent do people engage with the daily mindfulness messages? 3. Do participants receiving a structured curriculum of mindfulness messages delivered twice daily differ from those receiving randomly selected mindfulness messages delivered four times daily in engagement with the intervention? 4. How do the two mindfulness text messaging interventions differ in their effects on intervention engagement, craving, pain, mindfulness, and withdrawal symptoms? Participants will: 1. Receive daily medication reminder text messages for 12 weeks (i.e., 3 months) 2. Receive either 2 or 4 mindfulness messages per day for 6 weeks 3. Answer brief assessment questions six times per day during the 6-week mindfulness text messaging period 4. Complete questionnaires at enrollment (baseline), once each week during the 6-week mindfulness text messaging period (6 total), immediately after the 6-week mindfulness text messaging period (post-treatment), and 6 weeks after the mindfulness text messaging period ends (follow-up)
Trial Details
NCT Number NCT07711795
Lead Sponsor University of New Mexico
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Opioid Use Disorder (OUD), Chronic Pain
Enrollment 60 participants
Start Date 2025-04-23
Primary Completion 2027-07 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-17